Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Immunic Inc is a biotechnology business based in the US. Immunic shares (IMUX) are listed on the NASDAQ and all prices are listed in US Dollars. Immunic employs 60 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $3.57 |
|---|---|
| 52-week range | $2.52 - $14.50 |
| 50-day moving average | $4.26 |
| 200-day moving average | $7.49 |
| Wall St. target price | $23.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.57 from 2022-10-04
| 1 week (2022-09-29) | 12.62% |
|---|---|
| 1 month (2022-09-06) | -18.68% |
| 3 months (2022-07-06) | -8.23% |
| 6 months (2022-04-06) | -70.50% |
| 1 year (2021-10-06) | -52.02% |
|---|---|
| 2 years (2020-10-06) | -81.00% |
| 3 years (2019-10-04) | 9.93 |
| 5 years (2017-10-06) | 5.9 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -37.38% |
| Return on equity TTM | -66.93% |
| Profit margin | 0% |
| Book value | $4.18 |
| Market capitalisation | $96.6 million |
TTM: trailing 12 months
We're not expecting Immunic to pay a dividend over the next 12 months.
Immunic's shares were split on a 1:40 basis on 15 April 2019. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immunic shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Immunic shares which in turn could have impacted Immunic's share price.
Over the last 12 months, Immunic's shares have ranged in value from as little as $2.52 up to $14.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunic's is 1.8399. This would suggest that Immunic's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immunic, Inc. , a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR"t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York. .
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.